Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: Function through the RNAi pathway

Nucleic Acids Research

Volumn 40, Issue 22, 2012, Pages 11270-11280

  Hu, Jiaxin ^a   Liu, Jing ^a   Yu, Dongbo ^a   Chu, Yongjun ^a   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 1 PROTEIN; ARGONAUTE 2 PROTEIN; DUPLEX RNA; HUNTINGTIN; MESSENGER RNA; MICRORNA; MUTANT PROTEIN; PROTEIN GW182; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; BASE MISPAIRING; CAG REPEAT; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; HTT GENE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA INTERFERENCE; TRINUCLEOTIDE REPEAT; WILD TYPE;

ALLELES; ANIMALS; ARGONAUTE PROTEINS; BASE PAIR MISMATCH; CELL LINE; CELLS, CULTURED; MUTATION; NERVE TISSUE PROTEINS; RNA CLEAVAGE; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, MESSENGER; RNA-BINDING PROTEINS; TRINUCLEOTIDE REPEATS;

EID: 84871191498     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks907     Document Type: Article

References (53)

1. Walker, F. O. (2007) Huntington's disease. Lancet, 369, 218-228.
2. Orr, H. T. and Zoghbi, H. Y. (2007) Trinucleotide repeat disorders. Ann. Rev. Neurosci., 30, 575-621.
3. Finkbeiner, S. (2011) Huntington's disease. Cold Spring Harb. Perspect. Biol., 3, a007476.
4. Sah, D. W. and Aronin, N. (2011) Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest., 121, 500-507.
5. MacDonald, M. E., Ambrose, C. M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L., Barnes, G., Taylor, S. A., James, M., Groot, N. et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
6. Ratovitski, T., Chighladze, E., Arbez, N., Boronina, T., Herbich, S., Cole, R. N. and Ross, C. A. (2012) Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle, 11, 2006-2012.
7. Zheng, Z. and Diamond, M. I. (2012) Huntington disease and huntingtin protein. Prog. Mol. Biol. Transl. Sci., 107, 189-214.
8. Devranache, A., Aviolat, H., Zeder-Lutz, G., Busso, D., Altschuh, D., Trottier, Y. and Klein, F. A. C. (2011) Huntingtin affinity for partners is not changed by polyglutamine length: aggregration itself triggers aberrant interactions. Hum. Mol. Genet., 20, 2795-2806.
9. Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L. and Davidson, B. L. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA, 102, 5820-5825.
10. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G. et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA, 104, 17204-17209.
11. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P. et al. (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol., 65, 276-285.
12. Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J. and Davidson, B. L. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther., 17, 1053-1063.
13. Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Cheng, S. H., Shihabuddin, L. S., Hung, G. et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of mutant huntingtin synthesis. Neuron, 74, 1031-1044.
14. Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G. and Hayden, M. R. (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell, 81, 811-823.
15. Zeitlin, S., Liu, J.-P., Chapman, D. L., Papaioannnou, V. E. and Estratiadis, A. (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet., 11, 155-163.
16. White, J. K., Auerbach, W., Duyao, M. P., Vonsattel, J. P., Gusella, J. F., Joyner, A. L. and MacDonald, M. E. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet., 17, 404-410.
17. Godin, J. D., Columbo, K., Molina-Calavita, M., Keryer, G., Zala, D., Charrin, B. C., Dietrich, P., Volvert, M.-L., Guillemot, F., Dragatsis, I. et al. (2010) Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron, 67, 392-406.
18. Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z. et al. (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain, 135, 1197-1209.
19. Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L. and Paulson, H. L. (2003) Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA, 100, 7195-7200.
20. Schwarz, D. S., Ding, H., Kennington, L., Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z. and Zamore, P. D. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet., 2, e140.
21. Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., Hung, G., Bennett, C. F., Freier, S. M. and Hayden, M. R. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther., 19, 2178-2185.
22. Pfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J. P., Zamore, P. D. and Aronin, N. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol., 19, 774-778.
23. Lombardi, M. S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Di Maria, E., Donato, S. D. and Kaemmerer, W. F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exper. Neurol., 217, 312-319.
24. Krzyzosiak, W. J., Sobczak, K., Wojciechowska, M., Fiszer, A., Mykowska, A. and Kozlowski, P. (2011) Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res., 40, 11-26.
25. Michlewski, G. and Krzyzosiak, W. J. (2004) Molecular architecture of CAG repeats in human disease related transcripts. J. Mol. Biol., 340, 665-679.
26. Hu, J., Matsui, M., Gagnon, K. T., Schwartz, J. C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I. and Corey, D. R. (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol., 27, 478-484.
27. Gagnon, K. T., Pendergraff, H., Deleavey, G., Swayze, E., Potier, P., Randolph, J., Roesch, E., Chattopadhyaya, J., Damha, M., Bennett, C. F. et al. (2010) Allele-selective silencing of huntingtin expression with antisense oligonucleotides targeting the mRNA expanded CAG repeat. Biochemistry, 49, 10166-10178.
28. Hu, J., Liu, J. and Corey, D. R. (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183-1188.
29. Fiszer, A., Mykowska, A. and Krzyzosiak, W. J. (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res., 39, 5578-5585.
30. Matsui, M. and Corey, D. R. (2012) Allele selective inhibition of trinucleotide repeats. Drug Discov. Today, 17, 443-450.
31. Zhang, Y. and Friedlander, R. M. (2011) Using noncoding RNAs to develop therapies for Huntington's disease. Gene Ther., 18, 1139-1149.
32. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E., Lima, W., Crooke, S. T., Prakash, T. and Corey, D. R. (2012) Single-stranded RNAs that function through RNAi are potent and allele-selective inhibitors of huntingtin expression. Cell, 150, 895-908.
33. Chu, Y., Yue, X., Younger, S. T., Janowski, B. A. and Corey, D. R. (2010) Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res., 38, 7736-7748.
34. Omi, K., Hachiya, N. S., Tokunaga, K. and Kaneko, K. (2005) siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro. Biochem. Biophys. Res. Comm., 338, 1229-1235.
35. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L. and Hannon, G. J. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 1437-1441.
36. Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G. and Tuschl, T. (2004) Human argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell, 15, 185-197.
37. Eulalio, A., Huntzinger, E. and Izaurralde, E. (2008) Getting to the root of miRNA-mediated gene silencing. Cell, 132, 9-14.
38. Yao, B., Li, S., Jung, H. M., Lian, S. L., Abadal, G. X., Han, F., Fritzler, M. J. and Chan, E. K. L. (2011) Divergent GW182 functional domains in the regulation of translational silencing. Nucleic Acids Res., 39, 2534-2547.
39. Lazzareti, D., Tournier, I. and Izaurralde, E. (2009) The C-terminal domains of human TNRC6A, TNRC6B, and TNRC6C silence bound transcripts independently of argonaute proteins. RNA, 15, 1059-1066.
40. Takimoto, K., Wakiyama, M. and Yokoyama, S. (2009) Mammalian GW182 contains multiple argonaute binding sites and functions in microRNA-mediated translational repression. RNA, 15, 1078-1089.
41. Eulalio, A., Tritschler, F. and Izaurrailde, E. (2009) The GW182 protein family in animal cells: New insights into domains required for miRNA-mediated gene silencing. RNA, 15, 1433-1442.
42. Lian, S. L., Li, S., Abadal, G. X., Pauley, B. A., Fritzler, M. J. and Chan, E. K. L. (2009) The C-terminal half of human AGO2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. RNA, 15, 804-813.
43. Weiss, J. N. (1997) The Hill equation revisited. FASEB J., 11, 835-841.
44. Wang, Y., Juranek, S., Li, H., Sheng, G., Tuschl, T. and Patel, D. J. (2008) Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature, 456, 921-926.
45. Watts, J. K. and Corey, D. R. (2012) Silencing disease genes in the laboratory and the clinic. J. Pathol., 226, 365-379.
46. Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M. J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S. et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 375, 998-1006.
47. Miller, T. (2011) Cohort 1 of a Phase 1, double-blind, placebo controlled, dose-escalation study of the safety, tolerability, and pharmacokinetics of ISIS 333611 administered intrathecally to patients with familial ALS due to SOD1 mutations. In: American Academy of Neurology, 64th Annual Meeting [IN12-1. 001], New Orleans.
48. Stiles, D. K., Zhang, Z., Ge, P., Nelson, B., Grondin, R., Ai, Y., Hardy, P., Nelson, P. T., Guzaev, A. P., Butt, M. T. et al. (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exper. Neurol., 233, 463-471.
49. Hu, J., Liu, J., Gagnon, K. T., Watts, J. K., Swayze, E., Randolph, J., Chattopadhyaya, J., Bennett, C. F. and Corey, D. R. (2011) Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol. Chem., 392, 315-325.
50. Jackson, R. J. and Standart, N. (2007) How do miRNAs regulate gene expression. Sci. STKE re1, 21, 1395-1403.
51. Schnall-Levin, M., Rissland, O. S., Johnston, W. K., Perrimon, N., Bartel, D. P. and Berger, B. (2011) Unusually effective miRNA targeting within repeat rich coding regions of mammalian RNAs. Genome Res., 21, 1395-1403.
52. Saetrom, P., Heale, S. E., Snove, O., Aagaard, L., Alluin, J. and Rossi, J. J. (2007) Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res., 35, 2333-2342.
53. Broderick, J. A., Salomon, W. E., Ryder, S. P., Aronin, N. and Zamore, P. D. (2011) Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA, 17, 1858-1869.